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PURPOSE 
Exploration space missions pose several challenges to providing a comprehensive medication formulary designed to 
accommodate the size and space limitations of the spacecraft; while addressing the individual medications needs and 
preferences of the Crew; the negative outcome of a degrading inventory over time, the inability to resupply before 
expiration dates; and the need to properly forecast the best possible medication candidates to treat conditions that 
will occur in the future. 
 
METHODS 
The Pharmacotherapeutics Discipline has partnered with the Exploration Medical Capabilities (ExMC) Element to 
develop and propose a research pathway that is comprehensively focused on evidence-based models and theories, as 
well as on new diagnostic tools and treatments or preventive measures aimed at closure of the Med02 “Pharmacy” 
Gap; defined in the Human Research Program’s (HRP) risk-based research strategy.  The Med02 Gap promotes the 
challenge to identify a strategy to ensure that medications used to treat medical conditions during exploration space 
missions are available, safe, and effective.  It is abundantly clear that pharmaceutical intervention is an essential 
component of risk management planning for astronaut healthcare during exploration space.  However, the quandary 
still remains of how to assemble a formulary that is comprehensive enough to prevent or treat anticipated medical 
events; and is also chemically stable, safe, and robust enough to have sufficient potency to last for the duration of an 
exploration space mission.  In cases where that is not possible, addressing this Gap requires exploration of novel drug 
development techniques, dosage forms, and dosage delivery platforms that enhance chemical stability as well as 
therapeutic effectiveness.   
 
RESULTS 
The proposed research pathway outlines the steps, processes, procedures, and a research portfolio aimed at 
identifying a capability that will provide a safe and effective pharmacy for any specific exploration Design 
Reference Mission (DRM).  The proposed approach to building this research portfolio is to seek research projects 
that concentrate on four major focus areas; (1) Formulary selection, (2) Formulary potency and shelf life, (3) 
Formulary safety and toxicity, and (4) Novel technology and innovation such as portable real-time chemical analysis 
innovative drug therapies and dosage and delivery platforms. 
 
CONCLUSION 
The research pathway has been completed and presented to the HRP.  In spring 2017, it is scheduled to be reviewed 
by a panel of pharmaceutical and clinical experts that will evaluate the scientific merit and operational feasibility of 
the research pathway, as well as make suggestions for any warranted additions or improvements. Once finalized, the 
ExMC Element will proceed with the execution of this research pathway with the goal of gathering as much data, and 
learning as much as possible, to provide a safe and effective pharmaceutical formulary for use during exploration 
missions.  
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